Scott Berry and Danny McAuley discuss the results of the statin domain of the REMAP-CAP trial, investigating the effectiveness of simvastatin in treating severe COVID-19. They explore the rationale behind using statins as an intervention, the trial's design and eligibility criteria, and the decision to stop the trial early. The primary outcome and results are presented, highlighting the potential benefits for clinicians. They also discuss response adaptive randomization, the inflammatory phenotype of patients, and the challenges of conducting mechanistic work alongside clinical trials during a pandemic.
